Bellerophon Therapeutics (NASDAQ:BLPH) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a report released on Friday. The firm issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

Shares of NASDAQ:BLPH remained flat at $0.04 during trading hours on Friday. 1,139 shares of the company’s stock traded hands, compared to its average volume of 32,874. The firm has a fifty day moving average price of $0.04 and a two-hundred day moving average price of $0.05. The firm has a market capitalization of $452,510.00, a price-to-earnings ratio of -0.04 and a beta of 0.71. Bellerophon Therapeutics has a 12 month low of $0.03 and a 12 month high of $0.10.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.